Effects of Recombinant Human Erythropoietin on Platelet Activation in Acute Myocardial Infarction: Results of a Double-blind, Placebo-controlled, Randomized Trial

Overview

Journal Am Heart J

Specialty Cardiology & Vascular Diseases

Date 2009 Dec 5

PMID 19958860

Citations 4

Authors

Yi-Da Tang

Faisal Hasan

Frank J Giordano

Stephen Pfau

Henry M Rinder

Stuart D Katz

Affiliations

Soon will be listed here.

Abstract

Background: Erythropoietin mitigates myocardial damage and improves ventricular performance after experimental ischemic injury. This study assessed safety and efficacy markers relevant to the biological activity of recombinant human erythropoietin (rHuEpo) in patients with acute myocardial infarction (MI).

Methods: We conducted a prospective, placebo-controlled, randomized, double-blind trial to determine the effects of intravenous rHuEpo (200 U/kg daily for 3 consecutive days) on measures of platelet and endothelial cell activation, soluble Fas ligand, and peripheral blood mononuclear cell (PBMC) expression of angiogenesis signaling proteins in 44 subjects with acute MI treated with aspirin and clopidogrel after successful percutaneous coronary intervention.

Results: Recombinant human erythropoietin did not alter bleeding time, platelet function assay closure time, von Willebrand factor levels, soluble P-selectin, or soluble Fas ligand levels when compared with placebo. By contrast, rHuEpo significantly increased expression of erythropoietin receptor, vascular endothelial growth factor receptor Flt-1, and phosphorylated phosphatidylinositol 3-kinase in PBMCs when compared with placebo (all Ps < .05).

Conclusions: In acute MI patients treated with aspirin and clopidogrel, short-term administration of rHuEpo did not alter markers of platelet and endothelial cell activation associated with thrombosis, yet did increase expression of angiogenesis signaling proteins in PBMCs when compared with placebo. These data provide preliminary evidence of safety and biologic activity of rHuEpo at this dosing and support continued enrollment in ongoing efficacy trials.

Citing Articles

Myocardial protection by heparin-based coacervate of FGF10.

Wang Z, Huang Y, He Y, Khor S, Zhong X, Xiao J Bioact Mater. 2020; 6(7):1867-1877.

PMID: 33336117 PMC: 7732874. DOI: 10.1016/j.bioactmat.2020.12.002.

The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection.

Hu M, Shi M, Cho H, Zhang J, Pavlenco A, Liu S Kidney Int. 2013; 84(3):468-81.

PMID: 23636173 PMC: 3758776. DOI: 10.1038/ki.2013.149.

Myocardial infarction: cardioprotection by erythropoietin.

Talan M, Latini R Methods Mol Biol. 2013; 982:265-302.

PMID: 23456875 PMC: 6207951. DOI: 10.1007/978-1-62703-308-4_17.

Angiogenic therapy for cardiac repair based on protein delivery systems.

Formiga F, Tamayo E, Simon-Yarza T, Pelacho B, Prosper F, Blanco-Prieto M Heart Fail Rev. 2011; 17(3):449-73.

PMID: 21979836 DOI: 10.1007/s10741-011-9285-8.

References

Prunier F, Pfister O, Hadri L, Liang L, Monte F, Liao R . Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2006; 292(1):H522-9. DOI: 10.1152/ajpheart.00357.2006. View

Frossard M, Fuchs I, Leitner J, Hsieh K, Vlcek M, Losert H . Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004; 110(11):1392-7. DOI: 10.1161/01.CIR.0000141575.92958.9C. View

Westenbrink B, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, du Marchie Sarvaas G . Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007; 28(16):2018-27. DOI: 10.1093/eurheartj/ehm177. View

Sharpe P, Desai Z, Morris T . Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol. 1994; 47(2):159-61. PMC: 501833. DOI: 10.1136/jcp.47.2.159. View

Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M . Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002; 8(8):495-505. PMC: 2040012. View

Tang Y, Katz S . Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006; 113(20):2454-61. DOI: 10.1161/CIRCULATIONAHA.105.583666. View

Michelson A . Platelet function testing in cardiovascular diseases. Circulation. 2004; 110(19):e489-93. DOI: 10.1161/01.CIR.0000147228.29325.F9. View

Tramontano A, Muniyappa R, Black A, Blendea M, Cohen I, Deng L . Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003; 308(4):990-4. DOI: 10.1016/s0006-291x(03)01503-1. View

Liem A, van de Woestijne A, Bruijns E, Roeters van Lennep H, de Boo J, van Halteren H . Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol. 2007; 131(2):285-7. DOI: 10.1016/j.ijcard.2007.07.076. View

10.

Westmark C, Malter J . Up-regulation of nucleolin mRNA and protein in peripheral blood mononuclear cells by extracellular-regulated kinase. J Biol Chem. 2000; 276(2):1119-26. DOI: 10.1074/jbc.M009435200. View

11.

Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta E . Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A. 2003; 100(20):11612-7. PMC: 208806. DOI: 10.1073/pnas.1930406100. View

12.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J . Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98(10):708-14. DOI: 10.1093/jnci/djj189. View

13.

Payne D, Hayes P, Jones C, Belham P, Naylor A, Goodall A . Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg. 2002; 35(6):1204-9. DOI: 10.1067/mva.2002.122027. View

14.

Belonje A, Voors A, van Gilst W, Anker S, Slart R, Tio R . Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J. 2008; 155(5):817-22. DOI: 10.1016/j.ahj.2007.12.036. View

15.

Moia M, Mannucci P, Vizzotto L, Casati S, Cattaneo M, Ponticelli C . Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet. 1987; 2(8570):1227-9. DOI: 10.1016/s0140-6736(87)91849-6. View

16.

Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M . Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006; 48(1):176-84. DOI: 10.1016/j.jacc.2006.04.008. View

17.

Zhou X, Vaziri N . Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy. Nephrol Dial Transplant. 2002; 17(6):992-7. DOI: 10.1093/ndt/17.6.992. View

18.

Parsa C, Matsumoto A, Kim J, Riel R, Pascal L, Walton G . A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003; 112(7):999-1007. PMC: 198525. DOI: 10.1172/JCI18200. View

19.

Lipsic E, van der Meer P, Voors A, Westenbrink B, van den Heuvel A, de Boer H . A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006; 20(2):135-41. DOI: 10.1007/s10557-006-7680-5. View

20.

Marrero M, Venema R, Ma H, Ling B, Eaton D . Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int. 1998; 53(5):1259-68. DOI: 10.1046/j.1523-1755.1998.00887.x. View